Zenas BioPharma

1. Obexelimab MAA filing2H 2026Obexelimab MAA filing, 2H 2026, notable
2. ZB021 Ph1 readoutyear-end 2026ZB021 Ph1 readout, year-end 2026, notable
3. Obexelimab SLE Ph2 topline4Q 2026Obexelimab SLE Ph2 topline, 4Q 2026, thesis-defining
4. ZB021 / ZB022 ZB014 Ph12027ZB021 / ZB022 ZB014 Ph1, 2027, notable
5. Obexelimab FDA approvalMay 27, 2027Obexelimab FDA approval, May 27, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.